Monday, October 7, 2013
Even as biotech indices surpass
all-time highs, investors are saying there is more room to run. While buysiders
and bankers do expect the pace of growth to slow in the coming year, they think
the biotech sector could continue to outperform the broader markets for at
least a few more quarters.
The run now is being driven by
momentum investors seeking beta before year end in an economic environment that
favors equities. Investors and bankers said mid- and small cap names should be
prime targets for fund managers looking to beat their benchmarks.